The dysregulation of CDKs is a hallmark of cancer. Overactive CDKs can lead to uncontrolled cell proliferation, a key characteristic of cancerous tissues. Histological analysis of tumor samples often involves assessing the expression levels of CDKs and their associated cyclins. Targeting CDKs with specific inhibitors has become a promising strategy in cancer therapy. For example, CDK4/6 inhibitors are used in treating certain types of breast cancer.
